Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
Kioxia Holdings ¥120.4 billion IPO
The shares are listed on the Tokyo Stock Exchange
Bacardi $1 billion notes offering
The investment-grade notes are due 2030 and 2035
Sanrio ¥135.1 billion secondary offering
The shares are listed on the Tokyo Stock Exchange
Venture Global $1.75 billion IPO
We advised Venture Global on its IPO and NYSE listing
Province of Saskatchewan $1 billion global bond offering
The investment-grade debt is due 2030
Bank of America $10 billion floating-rate and fixed-to-floating-rate notes
The five-tranche investment-grade debt offering is based on the Secured Overnight Financing Rate
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S…
PAR Technology $115 million convertible senior notes offering
The notes are due 2030
Central American Bank for Economic Integration $1.5 billion notes
The notes are due 2028
Emera exchange offer
We advised Emera on its exchange offer